<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04047394</url>
  </required_header>
  <id_info>
    <org_study_id>SYSS-SSS11-UND-â… -02</org_study_id>
    <nct_id>NCT04047394</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers</brief_title>
  <official_title>An Open Label, Single-dose, Dose-increasing Study to Assess the Safety, Tolerability, PK and Preliminary PD of PEGylated Recombinant Candida Urate Oxidase (SSS11) for Injection in Chinese Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenyang Sunshine Pharmaceutical Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenyang Sunshine Pharmaceutical Co., LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability, PK and preliminary PD of SSS11 for injection in chinese&#xD;
      healthy adult volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, open label, single-dose, dose-increasing study to assess the safety,&#xD;
      tolerability and PK characteristics of healthy humans after injection of SSS11, provide a&#xD;
      reference for subsequent clinical studies and give preliminary assessment of the&#xD;
      immunogenicity and PD of SSS11.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>From the day signing in informed consent form to the day 56 post-dose</time_frame>
    <description>Number of subjects with Adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>From day 1 to day 56</time_frame>
    <description>Dose-LimitingToxicity of SSS11</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>From beginning of drug administration to day 56</time_frame>
    <description>Maximum plasma concentration (Cmax) of single dose SSS11</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>From beginning of drug administration to day 56</time_frame>
    <description>Peak plasma time [tmax] of single dose SSS11</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>From beginning of drug administration to day 56</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of single dose SSS11</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-urate oxidase antibody</measure>
    <time_frame>From pre-dose on week 2 up to week 1, 2, 4 and 7 post-dose.</time_frame>
    <description>The immunogenicity of SSS11 was assessed in subjects by detecting the anti-urate oxidase antibody.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric acid levels in blood</measure>
    <time_frame>From beginning of drug administration to day 56</time_frame>
    <description>This parameter was used to evaluate the PD of SSS11 in healthy humans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric acid levels in urine</measure>
    <time_frame>From beginning of drug administration to day 6</time_frame>
    <description>This parameter was used to evaluate the PD of SSS11 in healthy humans.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>PEGylated recombinant candida urate oxidase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered with 2mg, 3mg, 4.5mg, 6mg, 8mg, 10mg once by Intravenous injection. Subjects will be followed for 56 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEGylated recombinant candida urate oxidase</intervention_name>
    <description>PEGylated recombinant candida urate oxidase is a combination of 20kDa linear polyethylene glycol (PEG) linked to Candida utilis recombinant uricase by succinimide succinate</description>
    <arm_group_label>PEGylated recombinant candida urate oxidase</arm_group_label>
    <other_name>SSS11</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects in the age range between 18 and 45 years old (inclusive), male or female&#xD;
&#xD;
          -  In good health (no significant clinical symptoms or abnormal laboratory test results&#xD;
             without clinical significance)&#xD;
&#xD;
          -  BMI within the range between 19 and 28 kg/m2 (inclusive)&#xD;
&#xD;
          -  Voluntarily sign the written informed consent&#xD;
&#xD;
          -  Be able to understand and comply with the requirements of clinical protocols, expected&#xD;
             to complete the whole trial process&#xD;
&#xD;
          -  Subjects achieving full recovery if had the surgical treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects cannot tolerate intravenous injection&#xD;
&#xD;
          -  Allergies or previous history of drug allergy, or allergic history of PEG-drugs, or&#xD;
             previous history of allergies to two or more substances&#xD;
&#xD;
          -  Any abnormalities detected in three allergen tests (Special allergen screening - mixed&#xD;
             mould, total IgE assay, special allergen screening - HX2)&#xD;
&#xD;
          -  Subjects having anti- PEG antibody&#xD;
&#xD;
          -  Taking any medicine before enrollment, and the regimen was less than five half-life&#xD;
             periods or 4 weeks (Subject to the longest of the two)&#xD;
&#xD;
          -  Has a history of vaccination within 12 weeks before enrollment, or intend to receive&#xD;
             vaccines during the study&#xD;
&#xD;
          -  Taking any other clinical trials within 12 weeks before enrollment,or have used&#xD;
             similar drugs to the study drug&#xD;
&#xD;
          -  Having a history of blood donation within 12 weeks before enrollment&#xD;
&#xD;
          -  Having a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency or abnormal&#xD;
             G6PD detection&#xD;
&#xD;
          -  Having a history of catalase deficiency or evidence that individuals meet the criteria&#xD;
             for catalase deficiency&#xD;
&#xD;
          -  Having a history of serious diseases, including but not limited to digestive system,&#xD;
             cardiovascular system, respiratory system, urinary system, musculoskeletal system,&#xD;
             endocrine system, neuropsychiatric system, blood system, immune system diseases and&#xD;
             metabolic abnormalities&#xD;
&#xD;
          -  Having abnormalities and clinical significances in laboratory tests (blood routine,&#xD;
             urine routine, blood biochemistry, etc.) and electrocardiogram findings within two&#xD;
             weeks before enrollment&#xD;
&#xD;
          -  The HBsAg, anti-HIV, anti-HCV and treponema pallidum antibody were positive&#xD;
&#xD;
          -  The female within lactation, pregnancy, or having birth plan within 24 weeks&#xD;
&#xD;
          -  Blood pregnancy test was positive(female)&#xD;
&#xD;
          -  Male subjects who did not take effective contraception or their spouse plan to be born&#xD;
             within 24 weeks&#xD;
&#xD;
          -  Disabled person in mental or law&#xD;
&#xD;
          -  Subjects having a history of alcohol abuse within 24 weeks prior to screening, equal&#xD;
             to exceed 14 unit alcohol per week (1 unit = 12 ounces or 360 mL of beer, 1.5 ounces&#xD;
             or 45 mL of 40% alcohol, 5 ounces or 150 mL of wine)&#xD;
&#xD;
          -  Smoking more than 5 cigarettes per day within 24 weeks before screening&#xD;
&#xD;
          -  Those who have had halo and fainting history&#xD;
&#xD;
          -  Drug abuse test or alcohol test was positive&#xD;
&#xD;
          -  Drinking more than 1L of tea, coffee and/or caffeinated beverages daily&#xD;
&#xD;
          -  Those who do not understand the content of informed consent and other those who do not&#xD;
             meet the criteria for trial inclusion&#xD;
&#xD;
          -  Participants who researchers believe are not suitable (such as infirmity, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xianbo Li, MD</last_name>
    <phone>020-85959116</phone>
    <email>285641182@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianzhong Shentu, PhD</last_name>
    <phone>13957111817</phone>
    <email>stjz@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Fifth Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510799</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Xianbo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xianbo LI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 2, 2019</study_first_submitted>
  <study_first_submitted_qc>August 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasburicase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

